Newsroom | 1432 results

NORTH BETHESDA, Md.--(BUSINESS WIRE)--The Foundation for the National Institutes of Health awards the 2026 Kovler Prize for Trust in Life Science Journalism to STAT's Helen Branswell....

FOSTER CITY, Calif.--(BUSINESS WIRE)--Please replace the release with the following corrected version due to a change in the "PRODUCT SALES SUMMARY" table, where the Odefsey sales in Europe have been updated to $58 million for the three months ended June 30, 2026 (instead of $28 million). The updated release reads: GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 10% Year-Over-Year to $7.6 billion Biktarvy Sales Increased 7% Year-Over-Yea...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for the second quarter of 2026 and raised its full-year 2026 Revenue guidance by $500 million at the midpoint while reaffirming guidance(2) for Adjusted(3) diluted EPS, which absorbs an impact of approximately $0.10 related to the Innovent Biologics, Inc. transaction. EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: “Pfizer had another strong quarter, delivering on our financial commitments and adva...

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Commission (EC) has granted marketing authorization for the companies’ 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The adaptation is based on the recommendation from the Emergency Task Force (ETF) of the European Medic...

FLORHAM PARK, N.J.--(BUSINESS WIRE)--Shionogi Inc., a New Jersey-based subsidiary of Shionogi & Co., Ltd., (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, PhD; hereinafter “Shionogi”) announced U.S. availability of XOCOVA® (ensitrelvir), an oral antiviral, approved for post-exposure prophylaxis (PEP) of COVID‑19 in adults and adolescents 12 years of age and older following contact with an individual who has COVID-19.2 XOCOVA offers a new approach to help prevent COVID-1...

WASHINGTON--(BUSINESS WIRE)--The Independent Medical Alliance (IMA) today announced the publication of Volume 2, Issue 4 of the Journal of Independent Medicine, continuing to advance rigorous, conflict-free, double-blind peer-reviewed science.As the United States commemorates its 250th anniversary, the new issue features timely and notable medical research and observations, including:The Quiet Expansion of Death: Canada’s MAID Program and the Moral Fatigue of Modern MedicineTwo Hundred Fifty Yea...

THE WOODLANDS, Texas--(BUSINESS WIRE)--NPK International Inc. (NYSE: NPKI) (“NPK” or the “Company”) today announced that it will issue second quarter 2026 results after the U.S. markets close on Wednesday, July 29, 2026. A conference call will be held the following day on Thursday, July 30, 2026, at 9:30 a.m. ET to review the Company’s financial results and conduct a question-and-answer session. A webcast of the conference call and accompanying presentation materials will be available in the In...

WATERTOWN, Mass.--(BUSINESS WIRE)--Nocion Therapeutics, Inc., a biopharmaceutical company developing novel small molecule therapies that selectively silence activated sensory neurons, today announced that it will be presenting a poster at the European Respiratory Society (ERS) 2026 Cough Conference taking place from July 15-17, 2026, in London. The presentation details are as follows: Poster Title: The Nocion ASPIRE Study of Taplucainium in rCC: A Status Update Presenter: Matthew Frankel, M.D....

SAN JOSE, Calif.--(BUSINESS WIRE)--Visby Medical, the at-home diagnostics company, today announced U.S. Food and Drug Administration (FDA) clearance for the Visby Medical Flu and COVID-19 Test, the first multi-viral at-home PCR test. This marks Visby’s second over-the-counter PCR test and expands the company’s growing portfolio of rapid molecular diagnostics designed for home use. The clearance comes as demand for at-home testing continues to grow, particularly for respiratory infections like C...

LEIDEN, Netherlands--(BUSINESS WIRE)--Dutch biotech Leyden Laboratories B.V. (the “Company” or “Leyden Labs”) today announced a €40 million investment from the European Innovation Council (EIC) Fund, Invest-NL, Gates Foundation, ClavystBio, and others. The financing brings together a strong group of impact-focused investors from Europe, the United States, and Asia to support novel approaches that could better protect people worldwide against influenza and other respiratory viruses. Respiratory...